Compare
Aurinia Pharmaceuticals Inc. vs Summit Therapeutics Inc. vs Kiniksa Pharmaceuticals International, plc vs Cryoport, Inc.
| Latest fiscal year | Aurinia Pharmaceuticals Inc. AUPHRevenue covers only part of its income (partial revenue) | Summit Therapeutics Inc. SMMT | Kiniksa Pharmaceuticals International, plc KNSA | Cryoport, Inc. CYRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $677.56M | $176.18M |
| Revenue growth (YoY) | n/a | n/a | +60.1% | +12.4% |
| Gross margin | n/a | n/a | 88.5% (computed) | 47.1% |
| Operating margin | n/a | n/a | 11.4% | -20.9% |
| Net margin | n/a | n/a | 8.7% | 44.4% |
| Net income | $287.20M | -$1.08B | $59.01M | $78.30M |
| EPS (Diluted) | $2.07 | -$1.44 | $0.75 | $1.40 |
| Operating cash flow | $135.66M | -$322.93M | $137.99M | -$8.58M |
| Free cash flow | n/a | -$323.59M | $136.42M | -$25.02M |
| Cash & equivalents | $80.16M | $225.27M | $165.60M | $250.49M |
| Total assets | $751.59M | $751.18M | $763.63M | $764.99M |
| Total liabilities | $170.26M | $92.32M | $196.03M | $262.35M |
| Shareholders' equity | $581.33M | $658.86M | $567.61M | $502.64M |
| Return on year-end equity | 49.4% | -163.9% | 10.4% | 15.6% |
| Shares outstanding | 132.32M | 775.37M | n/a | 49.85M |
Revenue, most recent five fiscal years
| Fiscal year | Aurinia Pharmaceuticals Inc. | Summit Therapeutics Inc. | Kiniksa Pharmaceuticals International, plc | Cryoport, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2024-12-31 | $677.56M Ended 2025-12-31 | $176.18M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2023-12-31 | $423.24M Ended 2024-12-31 | $156.77M Ended 2024-12-31 |
| 2 years earlier | n/a | $705.0K Ended 2022-12-31 | $270.26M Ended 2023-12-31 | $168.66M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.81M Ended 2021-12-31 | $220.18M Ended 2022-12-31 | $237.28M Ended 2022-12-31 |
| 4 years earlier | n/a | $860.0K Ended 2020-12-31 | $38.54M Ended 2021-12-31 | $222.61M Ended 2021-12-31 |